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Sensitive assays for measurement of cardiac troponin T (cTnT) and troponin I (cTnI) have recently been intro-
duced in clinical practice and are essential for the diagnosis 
of acute myocardial infarction (MI).1 These assays are char-
acterized by improved analytic and diagnostic performance.2–9 
The prognostic use of sensitive troponin levels is not restricted 
to patients with MI but do also predict adverse outcomes in 
stable coronary artery disease.10
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Recently, sensitive troponin levels have also been found to 
be associated with prognosis in patients with chronic heart 
failure (HF),11–13 and changes in cTnT concentrations over 
time, as measured with a high-sensitive assay (hs-cTnT), 
were shown to predict cardiovascular (CV) events in these 
patients.14 However, changes in hs-cTnT added limited prog-
nostic discrimination. Because the incidence and prevalence 
of HF are increasing as a result of changing demographics 
and an increasing proportion of the elderly, we think that fur-
ther exploration of the prognostic role of elevated hs-cTnT in 
older patients with chronic HF is of importance. We therefore 
evaluated the prognostic relevance of elevated hs-cTnT lev-
els on outcomes in a substudy involving ≈30% of the patients 
enrolled in the Controlled Rosuvastatin Multinational Trial in 
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Background—The incremental prognostic value of high-sensitive troponin T (hs-cTnT) in heart failure (HF) beyond that of 
high-sensitivity C-reactive protein and amino-terminal probrain natriuretic peptide is debated. We examined the prognostic 
value of hs-cTnT in a subgroup of patients from the Controlled Rosuvastatin Multinational Trial in HF (CORONA) study.
Methods and Results—Hs-cTnT as a risk factor for the primary end point (cardiovascular death, nonfatal myocardial infarction, 
and nonfatal stroke; n=356), as well as all-cause mortality (n=366), cardiovascular mortality (n=299), and the composite 
of cardiovascular mortality and hospitalization from worsening of HF (n=465), was investigated in 1245 patients (≥60 
years; New York Heart Association [NYHA] class II–IV, ischemic systolic HF) randomly assigned to 10 mg rosuvastatin or 
placebo. In multivariable analyses, adjusting for left ventricular ejection fraction, NYHA class, age, body mass index, diabetes 
mellitus, sex, intermittent claudication, heart rate, estimated glomerular filtration rate, apolipoprotein B/apolipoprotein A-1 
ratio, amino-terminal probrain natriuretic peptide, high-sensitivity C-reactive protein, and hs-cTnT (both dichotomized 
according to the 99th percentile and as a continuous variable) was associated with all end points (primary end point: hazard 
ratio, 1.87 and 1.51, respectively, per SD change; P<0.001; all other end points: hazard ratio, 1.39–1.70). However, improved 
discrimination as assessed by C-statistics was only seen for the primary end point and all-cause mortality.
Conclusions—Elevated hs-cTnT levels provide strong and independent prognostic information in older patients with 
chronic ischemic HF.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00206310.   
(Circ Heart Fail. 2014;7:96-103.)
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HF (CORONA), performed in older patients with systolic HF 
of ischemic origin. In CORONA, rosuvastatin did not reduce 
the primary composite outcome (death from CV causes, non-
fatal MI, and nonfatal stroke) or all-cause mortality. The pre-
dictive value of elevated baseline hs-cTnT and the prognostic 
value of changes in hs-cTnT levels from baseline to 3-month 
follow-up were evaluated, as well as possible interactions with 
statin therapy. We hypothesized that hs-cTnT would provide 
additional prognostic and discriminating information beyond 
that of established HF risk factors in this patient cohort.
Methods
Patients
The design and principal findings of CORONA have been reported in 
detail.15 Briefly, patients aged ≥60 years with chronic HF attributed to 
ischemic heart disease, defined as (1) medical history or ECG signs 
of old MI or (2) other data indication ischemic cause of HF (ie, wall 
motion disturbances on echocardiography, left bundle branch block, 
or history of other occlusive atherosclerotic disease [ie, earlier stroke, 
intermittent claudication, percutaneous coronary intervention]), who 
were in New York Heart Association (NYHA) class II–IV, with a left 
ventricular ejection fraction ≤40% (≤35% if NYHA II), were eligible, 
provided the investigator thought they did not need treatment with 
a cholesterol-lowering drug. The main criteria for exclusion were a 
recent CV event, current or planned procedures or operations, acute 
or chronic liver disease, serum creatinine ≥2.5 mg/dL, contraindica-
tions to statin therapy, or unexplained increase in creatine kinase. All 
patients provided written informed consent. Patients were randomly 
assigned to rosuvastatin 10 mg/d or matching placebo, once daily.
Study Procedures
The trial complied with the Declaration of Helsinki and was approved 
by the Ethics Committees of the participating hospitals. All patients 
provided written informed consent. Patients were randomly assigned 
to rosuvastatin 10 mg/d or matching placebo, once daily. The present 
study was a predefined substudy of the main CORONA trial, which 
included 1480 consecutive patients (hs-cTnT was measured in 1245 
patients with samples available at both baseline and 3 months). There 
were only minor differences in the baseline characteristics between 
this substudy and the main CORONA study (Table I in the Data 
Supplement).
Study Outcomes and Definitions
The primary predefined outcome was the composite of death from 
CV causes, nonfatal MI, and nonfatal stroke, analyzed as time to the 
first event. Of secondary outcomes, the following were used in this 
substudy: (1) all-cause mortality, (2) CV mortality, and (3) composite 
of CV mortality and hospitalizations from worsening of HF (WHF). 
The definition and adjudication of all outcomes, as well as data on 
high-sensitivity C-reactive protein (hs-CRP) and amino-terminal 
probrain natriuretic peptide (NT-proBNP), have been described in 
detail.15–18
Blood Sampling and Biochemical Analyses
TnT was measured in blood samples taken after an overnight fast with 
a high-sensitivity assay (Roche Diagnostics, Basel, Switzerland) on 
a Roche Modular E170 platform using the Elecsys reagents (Roche 
Diagnostics). This hs-cTnT assay has a detection limit of 3 ng/L, a 
99th percentile cutoff of 14 ng/L, and a coefficient of variation of 
<10% at 13 ng/L. Hs-cTnT levels below detection limit were set to 3 
ng/L in the statistical analyses. All other blood samples were nonfast-
ing and analyzed on fresh samples at a central laboratory (Medical 
Research Laboratories, Zaventem, Belgium). NT-proBNP was ana-
lyzed using commercially available assay (Roche Diagnostics, Basel, 
Switzerland). An immunonephelometric high-sensitivity method was 
used to measure CRP (Dade Behring, Atterbury, UK; sensitivity, 
0.04 mg/L).
Statistical Analysis
For all baseline variables, differences between patients with hs-cTnT 
levels > or ≤14 ng/L (99th percentile) were tested with the Student t 
test for normally distributed variables, Fisher exact test for categori-
cal data, and Wilcoxon rank-sum test for non-normally distributed 
variables. The natural log was used for logarithmic transformations. 
All variables with a significant univariate association with hs-cTnT 
levels were included in a stepwise logistic regression to explore their 
combined explanatory power of hs-cTnT levels. All survival analyses 
were conducted using the Cox proportional hazard regression model 
where hs-cTnT was included as a dichotomized variable (±14 ng/L) 
in a multivariable analysis that included left ventricular ejection frac-
tion, NYHA class, age, body mass index, diabetes mellitus, sex, in-
termittent claudication, heart rate, estimated glomerular filtration rate 
(eGFR), apolipoprotein B/apolipoprotein A-1 ratio, log-transformed 
(natural log) plasma concentrations of NT-proBNP, and hs-CRP. The 
Harrell C-statistic was calculated for all end points using the multi-
variable model with and without hs-cTnT, and the difference between 
the C-statistics was estimated. To correct for overoptimism associ-
ated with validating a model in the same material from which it is 
developed, we implemented a jack-knife cross-validation approach, 
where predictions for each observation were obtained from mod-
els developed on the remaining observations. These cross-validated 
probabilities were used to calculate jack-knife C-statistics. Recently, 
calculation of net reclassification improvement (NRI) has been sug-
gested for the evaluation of the prognostic usefulness of a biomark-
er.19 In particular, when no established risk categories exist, the use 
of a category-free NRI has been advocated.20 We therefore calculated 
the category-free NRI after adding hs-cTnT to the multivariable mod-
el. Confidence intervals and P values for NRI were determined by 
bootstrapping with 2000 repetitions. For the analysis of changes in 
hs-cTnT concentrations from baseline to 3-month follow-up, a 15% 
relative change was used as cutoff, which is consistent with other 
studies.14 A 2-sided P <0.05 was considered to be significant, except 
for interaction terms for which values of P <0.10 were accepted. 
All statistical analyses were performed using STATA version 11 for 
Windows (StataCorp, College Station, TX). The authors had full ac-
cess to and take responsibility for the integrity of the data. All authors 
have read and agreed to the article as written.
Results
Baseline Characteristics
In our study population, 1078 patients (86.6%) had hs-cTnT 
levels above the detection limit (3 ng/L) of the assay. The 
baseline characteristics of patients dichotomized according to 
the 99th percentile to hs-cTnT (14 ng/L) are shown in Table 1. 
Patients with hs-cTnT levels >14 ng/L were older, more fre-
quently men, had lower left ventricular ejection fraction, 
lower body mass index, and higher heart rate than those with 
hs-cTnT levels ≤14 ng/L. In addition, patients with  hs-cTnT 
levels >14 ng/L had a higher prevalence of atrial fibrillation, 
other atherosclerotic diseases, previous percutaneous coro-
nary intervention, diabetes mellitus, hypertension, and chronic 
obstructive pulmonary disease. Patients with hs-cTnT above 
the 99th percentile were more frequently treated with aldo-
sterone antagonists, diuretics, and digitalis glycosides. On the 
contrary, a history of angina pectoris and the use of β-blockers 
were less prevalent in patients with hs-cTnT >14 ng/L than in 
those with hs-cTnT levels ≤14 ng/L. Patients with hs-cTnT 
levels >14 ng/L had lower total and low-density lipoprotein 
cholesterol levels and a lower average eGFR but had higher 
levels of NT-proBNP and hs-CRP.
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Table 1. Baseline Patient Characteristics
Variable Total Cohort (N=1245) hs-cTnT ≤14 (n=629) hs-cTnT >14 (n=616) P Value
Age, y 71.8 (6.9) 70.3 (6.5) 73.3 (6.9) <0.001
Female sex 284 (22.8) 192 (30.5) 92 (14.9) <0.001
Smoking 175 (12.1) 66 (10.5) 79 (12.8) 0.216
NYHA Class 0.715
  II 400 (32.1) 196 (31.2) 204 (33.1)
  III 830 (66.7) 426 (67.7) 404 (65.6)
  IV 15 (1.2) 7 (1.1) 8 (1.3)
Ejection fraction, % 32 (7) 33 (6) 30 (7) <0.001
BMI, kg/m2 27.3 (4.5) 27.6 (4.6) 26.9 (4.4) 0.005
SBP, mm Hg 129 (16.0) 131 (15.2) 128 (16.6) 0.003
DBP, mm Hg 77 (8.8) 78 (8.3) 75 (9.1) <0.001
Heart rate, beats/min 71 (11) 69 (10) 72 (11) <0.001
Medical history
  Myocardial infarction 780 (62.7) 387 (61.5) 393 (63.8) 0.413
  History of angina pectoris 910 (73.1) 496 (78.9) 414 (67.2) <0.001
  Other atherosclerotic disease 243 (19.5) 103 (16.4) 140 (22.7) 0.005
  PCI/CABG 262 (21.0) 113 (18.0) 149 (24.2) 0.008
  Hypertension 868 (69.7) 459 (73.0) 409 (66.4) 0.014
  Diabetes mellitus 325 (26.1) 141 (22.4) 184 (29.9) 0.003
  Atrial fibrillation 263 (21.1) 104 (16.5) 159 (25.8) <0.001
  Stroke 145 (11.6) 65 (10.3) 80 (13.0) 0.158
  Claudication 128 (10.3) 51 (8.1) 77 (12.5) 0.012
  COPD 24 (1.9) 6 (1.0) 18 (2.9) 0.013
Laboratory measures
  High-sensitive troponin T, ng/L 13.9 (6.6–25.6) 6.6 (3.0–9.9) 25.7 (18.5–36.5) <0.001
  Total cholesterol, mmol/L 5.22 (1.09) 5.32 (1.05) 5.12 (1.11) 0.001
  LDL, mmol/L 3.64 (0.97) 3.77 (0.97) 3.50 (0.94) <0.001
  HDL, mmol/L 1.23 (0.35) 1.24 (0.33) 1.22 (0.36) 0.352
  Triglycerides, mmol/L 2.00 (1.34) 2.03 (1.20) 1.96 (1.46) 0.336
  ApoB/ApoA-1 value 0.88 (0.25) 0.89 (0.24) 0.88 (0.26) 0.816
  eGFR, mL/min per 1.73 m2 58 (14) 62 (13) 53 (14) <0.001
  NT-proBNP, pmol/L 156 (61–339) 89 (36–191) 272 (137–535) <0.001
  hs-CRP, mg/L 3.6 (1.6–7.6) 3.0 (1.5–6.0) 4.5 (1.9–9.4) <0.001
Medications
  Diuretics (loop/thiazide) <0.001
   None 161 (12.9) 106 (16.9) 55 (8.9)
   One 951 (76.4) 463 (73.6) 488 (79.2)
   Both 133 (10.7) 60 (9.5) 73 (11.9)
  Aldosterone antagonist 454 (36.5) 196 (31.2) 258 (41.9) <0.001
  ACE inhibitor 1001 (80.4) 512 (81.4) 489 (79.4) 0.392
  Angiotensin II receptor blocker 128 (10.3) 59 (9.4) 69 (11.2) 0.306
  β-Blocker 962 (77.3) 511 (81.2) 451 (73.2) 0.001
  Digitalis glycoside 349 (28.0) 126 (20.0) 223 (36.2) <0.001
Demographic, clinical, and biochemical baseline characteristics stratified by serum high-sensitive troponin T (hs-cTnT) levels below or above 
the 99th percentile (14 ng/L). High-sensitivity C-reactive protein (hs-CRP), amino-terminal probrain natriuretic peptide (NT-proBNP), and hs-cTnT 
levels are displayed as median value (25th–75th percentiles). Other variables are shown as numbers (% of total) or mean (SD), where appropriate. 
ACE indicates angiotensin-converting enzyme; ApoA-1, apolipoprotein A-1; ApoB, apolipoprotein B; BMI, body mass index; CABG, coronary artery 
bypass grafting; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; and SBP, systolic 
blood pressure.
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When all variables in Table 1 that were significantly asso-
ciated with elevated hs-cTnT levels were included in a lin-
ear regression model, NT-proBNP levels, diabetes mellitus, 
history of coronary revascularization, age, use of digitoxin/
digoxin, diuretics and β-blockers, hs-CRP levels, systolic and 
diastolic blood pressures, heart rate, female sex, and eGFR 
remained independently associated with hs-cTnT levels, 
explaining 47.1% (R2) of the variation (Table 2). Of these 
variables, NT-proBNP was the strongest predictor of elevated 
hs-cTnT levels.
Effect of Rosuvastatin Treatment on hs-cTnT Levels 
and Clinical Outcomes
The difference in hs-cTnT concentrations at baseline and 
3-month follow-up was not statistically different, neither 
among patients receiving placebo nor in the rosuvastatin group. 
Importantly, there was no statistically significant interaction 
between hs-cTnT levels and treatment with rosuvastatin.
Association Between High-Sensitivity cTnT Levels 
and Outcomes
During a median follow-up of 955 (25th–75th percentiles, 
817–1003) days, 366 patients died. Restricted cubic spline 
analysis demonstrated linearity between risk for all-cause 
mortality and log-transformed hs-cTnT levels (Figure 1). 
Kaplan–Meier plots for the primary end point, all-cause mor-
tality, CV mortality, and the composite of CV mortality and 
hospitalization from WHF demonstrated a significantly higher 
frequency of events for patients with hs-cTnT levels >14 ng/L 
compared with those with hs-cTnT levels ≤14 ng/L (Figure 2). 
Hs-cTnT levels, both dichotomized according to the 99th per-
centile (Table 3) and as a continuous variable (Table 4), were 
associated with the primary end point, as well as all-cause 
mortality, CV mortality, and the composite of CV mortality 
and hospitalization from WHF in a multivariable regression 
model adjusting for demographic and clinical variables, as 
well as NT-proBNP, hs-CRP, and eGFR. Similar associations 
were also found when the relationship between hs-cTnT and 
outcomes was assessed according to quartiles of hs-cTnT lev-
els (Table II in the Data Supplement). Importantly, hs-cTnT 
levels dichotomized according to the 99th percentile (14 ng/L) 
remained a significant predictor of outcome in an extended 
multivariable regression model, also including systolic and 
diastolic blood pressures, history of angina pectoris, history 
of atherosclerotic disease, history of previous revasculariza-
tion, hypertension, atrial fibrillation, chronic obstructive pul-
monary disease, total cholesterol,  low-density lipoprotein 
levels, use of diuretics, use of aldosterone antagonists, use of 
β-blockers, and use of digitalis glycoside (Table 3). Compari-
sons among hs-cTnT, hs-CRP, and NT-proBNP, as predictors 
of outcome in this study population, have also been performed 
(Table III in the Data Supplement).
Value of hs-cTnT in Prognostic Discrimination
To assess the value of hs-cTnT in prognostic discrimination, 
NRI analyses were performed. Introduction of hs-cTnT levels 
to the multivariable model (including hs-CRP and  NT-proBNP) 
significantly improved prognostic discrimination of the pri-
mary end point, as well as all-cause mortality, CV mortality, 
and the composite of CV mortality and hospitalization from 
WHF, as indicated by the NRI scores (Table 4). However, 
improved discrimination as assessed by  C-statistics was only 
seen for the primary end point and  all-cause mortality.
Changes in hs-cTnT Levels Over Time and 
Relationship With Outcomes
Overall, 300 patients (29%) had a >15% increase in hs-cTnT 
between baseline and 3 months. Of these, 183 (61%) patients 
had a baseline hs-cTnT ≤14 ng/L and 117 (39%) had a base-
line hs-cTnT >14 ng/L. Such an increase was associated with 
Table 2. Independent Correlates of Elevated hs-cTnT Levels
Variable Coef SE P Value 95% CI
NT-proBNP (log transformed) 0.309 0.019 0.031 0.272 to 0.346
Diabetes mellitus 0.262 0.050 <0.001 0.165 to 0.360
History of PCI/CABG 0.112 0.057 0.048 0.00084 to 0.223
Age 0.107 0.036 0.003 0.0366 to 0.177
Digitoxin/digoxin 0.105 0.049 0.034 0.00796 to 0.202
Diuretics (loop/thiazide) 0.103 0.045 0.022 0.0150 to 0.191
hs-CRP (log-transformed) 0.0396 0.0183 0.031 0.00373 to 0.0755
Baseline SBP 0.00581 0.0091 0.002 0.00206 to 0.00956
Heart rate 0.00507 0.0022 0.022 0.00075 to 0.00939
β-Blocker −0.155 0.054 0.004 −0.260 to −0.0501
Female sex −0.553 0.0533 <0.001 −0.658 to −0.448
eGFR −0.0142 0.00171 <0.001 −0.0176 to −0.0108
Baseline DBP −0.00996 0.0035 0.004 −0.0168 to −0.00312
A linear regression model was performed to identify factors that are significantly associated with increasing log-transformed 
levels of serum high-sensitive troponin T (hs-cTnT). CABG indicates coronary artery bypass grafting; CI, confidence interval; 
Coef, regression coefficient with corresponding P value; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration 
rate; hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, amino-terminal probrain natriuretic peptide; PCI, percutaneous 
coronary intervention; and SBP, systolic blood pressure.
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a higher risk of the composite end point of CV mortality or 
hospitalization because of WHF but not with any of the other 
prespecified end points, including the primary end point (Fig-
ure 3). The predictive value of absolute changes in hs-cTnT 
levels from baseline to 3 months was inferior to that of relative 
change (data not shown).
Discussion
Our data demonstrate that elevated hs-cTnT levels had a strong 
predictive and discriminating value for the primary end point, 
all-cause mortality, CV mortality, and the composite of CV 
mortality and hospitalizations because of WHF among older 
patients with chronic HF of ischemic origin. Although hs-
cTnT levels in the CORONA population in relation to serum 
levels of gp130, a marker of activity in the  interleukin-6 sys-
tem, have already been reported,21 the present post hoc analy-
sis from CORONA includes more comprehensive data on the 
hs-cTnT levels in this patient population.
The predictive value of elevated hs-cTnT levels was 
explored both dichotomized according to the 99th percentile 
and as a continuous variable in the present study. The choice 
of 14 ng/L as a cutoff was motivated by its clinical importance 
because 14 ng/L is equal to the 99th percentile of hs-cTnT in a 
healthy population.22 We wanted to test the prognostic impor-
tance of normal versus pathological levels of hs-cTnT in an 
HF population. Because the restricted cubic spline plot for hs-
cTnT in relation to all-cause mortality showed a linear rela-
tionship, we also investigated the predictive value of  hs-cTnT 
as a continuous variable.
The study includes several clinical end points. Importantly, the 
primary end point is equal to the predefined primary end point in 
the original CORONA study.15 The rationale for combining CV 
Figure 1. Restricted cubic spline analysis (fitted curve with 95% 
confidence interval) demonstrating linearity between risk for all-
cause mortality and log-transformed high-sensitive troponin T 
(hs-cTnT) levels.
Figure 2. Kaplan–Meier curves demonstrating the cumulative incidence of the primary end point, all-cause mortality, cardiovascu-
lar (CV) mortality, and composite of CV mortality and hospitalization from worsening of heart failure (WHF) in all patients according to 
 high-sensitive troponin T (hs-cTnT) levels > or ≤14 ng/L.
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mortality and hospitalizations is an attempt to combine mortality 
and morbidity to reflect the true burden of the HF syndrome. The 
effect of mortality is obvious, but the effect of hospitalizations 
might be underestimated in clinical trials.23
Although several previous studies have identified elevated 
cTnT or cTnI as markers of adverse events in chronic HF 
even after adjustment for BNP or NT-proBNP, those stud-
ies differed significantly from ours, having included smaller 
Table 4. Multivariable Analyses: Effects of hs-cTnT Levels, as a Continuous Variable, on Outcomes
log hs-cTnT n Events HR (95% CI) P Value Wald ΔC Index NRI (P Value) Events Nonevents
Primary end point
  Unadjusted 1245 356 2.06 (1.83–2.31) <0.001 149
  Adjusted for risk factors 1026 272 1.51 (1.27–1.78) <0.001 22.3 0.013 (0.048) 0.26 (0.0014) 0.26 (<0.001) 0.13 (0.003)
All-cause mortality
  Unadjusted 1245 366 2.05 (1.83–2.30) <0.001 154
  Adjusted for risk factors 1026 281 1.45 (1.23–1.70) <0.001 19.4 0.011 (0.031) 0.17 (0.044) 0.23 (<0.001) 0.12 (0.004)
CV mortality
  Unadjusted 1245 299 2.10 (1.85–2.38) <0.001 134
  Adjusted for risk factors 1026 227 1.43 (1.19–1.71) <0.001 14.8 0.010 (0.051) 0.22 (0.017) 0.25 (<0.001) 0.11 (0.003)
CV mortality or hospitalization from WHF
  Unadjusted 1245 465 2.41 (1.96–2.98) <0.001 113
  Adjusted for risk factors 1026 367 1.39 (1.07–1.79) 0.013 6.19 0.0034 (0.23) 0.33 (<0.001) 0.21 (<0.001) 0.11 (0.014)
The table shows log-transformed levels of serum high-sensitive troponin T (hs-cTnT) as a continuous variable as a predictor of outcome. All hazard ratios (HRs) 
are given as HR (95% confidence interval [CI]). ΔC index: difference in C index between adjusted models with and without inclusion of hs-cTnT with corresponding 
P value. Net reclassification improvement (NRI) calculated for fully adjusted models with and without inclusion of hs-cTnT with corresponding P value. The multivariable 
regression model includes the following risk factors: left ventricular ejection fraction, New York Heart Association class, age, body mass index, diabetes mellitus, sex, 
intermittent claudication, heart rate, apolipoprotein B/apolipoprotein A-1 ratio, amino-terminal probrain natriuretic peptide, high-sensitivity C-reactive protein, and 
estimated glomerular filtration rate. CV indicates cardiovascular; and WHF, worsening of heart failure.
Table 3. Multivariable Analyses: Effects of hs-cTnT >14 ng/L on Outcomes
hs-cTnT >14 ng/L n Events HR (95% CI) P Value Wald
Primary end point
  Unadjusted 1245 356 3.38 (2.67–4.27) <0.001 103
  Adjusted for risk factors 1026 272 1.87 (1.38–2.55) <0.001 16.0
  Adjusted for risk 
factors—extended
1026 272 1.89 (1.38–2.59) <0.001 15.7
All-cause mortality
  Unadjusted 1245 366 3.27 (2.60–4.12) <0.001 101
  Adjusted for risk factors 1026 281 1.69 (1.25–2.29) 0.001 11.6
  Adjusted for risk 
factors—extended
1026 281 1.63 (1.20–2.23) 0.002 9.52
CV mortality
  Unadjusted 1245 299 3.49 (2.70–4.53) <0.001 89.3
  Adjusted for risk factors 1026 227 1.70 (1.21–2.39) 0.002 9.49
  Adjusted for risk 
factors—extended
1026 227 1.67 (1.18–2.36) 0.004 8.22
CV mortality or hospitalization from WHF
  Unadjusted 1245 465 2.92 (2.40–3.56) <0.001 113
  Adjusted for risk factors 1026 367 1.39 (1.07–1.79) 0.013 6.19
  Adjusted for risk 
factors—extended
1026 367 1.39 (1.07–1.80) 0.014 5.99
High-sensitive troponin T (hs-cTnT) as a predictor of outcome, included as a dichotomized variable (14 ng/L). All hazard ratios (HRs) 
are given as HR (95% confidence interval [CI]) with corresponding P value. The multivariable regression model includes the following risk 
factors: left ventricular ejection fraction, New York Heart Association class, age, body mass index, diabetes mellitus, sex, intermittent 
claudication, heart rate, apolipoprotein B/apolipoprotein A-1 ratio, amino-terminal probrain natriuretic peptide, high-sensitivity C-reactive 
protein, and estimated glomerular filtration rate. The extended multivariable regression model also includes the following risk factors: systolic 
blood pressure, diastolic blood pressure, history of angina pectoris, history of atherosclerotic disease, history of previous revascularization, 
hypertension, atrial fibrillation, chronic obstructive pulmonary disease, total cholesterol, low-density lipoprotein levels, use of diuretics, use of 
aldosterone antagonists, use of β-blockers, and use of digitalis glycoside. CV indicates cardiovascular; and WHF, worsening of heart failure.
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numbers of patients, few elderly patients, or a small propor-
tion of patients in NYHA functional class III or IV.12,24,25 In 
particular, our data differ somewhat from those in a report 
from the Val-HeFT (Valsartan Reduces Morbidity in Chronic 
Heart Failure) and GISSI-HF (Gruppo Italiano per lo Studio 
della Sopravvivenza nellInsufficienza Cardiaca-Heart Failure) 
trials, which showed that changes in hs-cTnT concentrations 
over time predicted CV events among patients with HF but, 
however, added limited prognostic discrimination.14 In this 
CORONA substudy, we were unable to reproduce the impor-
tance of change in hs-cTnT concentration over time in the 
prediction of outcome, despite similar cutoff levels for change 
(>15% relative change) and interval (3 months). Importantly, 
changes in hs-cTnT provided inferior prognostic informa-
tion than that of elevated baseline levels in the present study. 
Nonetheless, from a clinical point of view, the prognostic value 
of baseline levels above or below the 99th percentile seems to 
be more important than that of changes during follow-up.
An explanation for these divergent findings might be differ-
ences in the composition of the study populations. Compared 
with the present CORONA substudy, the Val-HeFT and 
GISSI-HF study populations were younger (72±7 versus 
63±11 [Val-HeFT] and 67±11 [GISSI-HF] years old), fewer 
were in NYHA class III and IV (67.9% versus 38.0% and 
26.1%, respectively), had higher average eGFR (58.0 versus 
61.7 and 61.9 mL/min per 1.73 m2, respectively), and the rate 
of HF with ischemic cause in these studies was ≈50%.
The mechanisms underlying hs-cTnT elevation in chronic 
HF remain unresolved.26 A net effect of increased release of 
myocardial troponin into the circulation because of myocyte 
necrosis, apoptosis, or irreversible injury with increased myo-
cyte membrane permeability and impaired renal clearance 
is a potential explanation.27 The causes of cardiac myocyte 
necrosis, apoptosis, and increased membrane permeability 
might involve neurohormonal activation, oxidative stress, 
inflammatory cytokines, increased wall stress, altered cal-
cium handling, and coronary artery disease.27 This hypoth-
esis is supported by the current study because in addition to 
eGFR, which is known to influence hs-cTnT levels,28 diabe-
tes mellitus (inflammation and oxidative stress), NT-proBNP 
levels (increased wall stress), hs-CRP levels (inflammation), 
increased heart rate and blood pressure (neurohormonal acti-
vation), and history of coronary revascularization (coronary 
artery disease) are associated with elevated hs-cTnT levels.
Limitations
The results of the present study are derived from a selected 
population of elderly patients with HF of ischemic origin 
included in the CORONA trial and may therefore not be 
applicable to a general HF population of mixed cause. In this 
respect, the frequency of comorbidities also warrants caution 
when interpreting the findings.
Conclusions
Elevated hs-cTnT levels in elderly patients with chronic HF of 
ischemic cause provide independent prognostic and discrimi-
nating information beyond that of established risk markers. 
The prognostic value of baseline hs-cTnT levels was superior 
to that of changes during follow-up.
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CLINICAL PERSPECTIVE
Serum levels of cardiac troponins, as measured by sensitive assays, are essential for the diagnosis of acute myocardial infarc-
tion. Cardiac troponins are also shown to provide important prognostic information in a variety of cardiac and noncardiac 
diseases, including chronic heart failure (HF). Because the incidence and prevalence of HF are increasing as a result of 
changing demographics and an increasing proportion of the elderly, the relevance of cardiac troponins in older patients with 
chronic HF may be of significant clinical importance. Accordingly, we explored the role of serum levels of cardiac troponin 
T, as measured with a high-sensitive assay, in the prediction of fatal and nonfatal outcomes in a large contemporary cohort 
of elderly patients with systolic HF of ischemic origin, receiving modern pharmacological therapy, randomly assigned to 
statin therapy or placebo in a double-blinded fashion. Baseline high-sensitive troponin T levels, both dichotomized accord-
ing to the 99th percentile (14 ng/L) and as a continuous variable, independently predicted fatal and nonfatal outcomes 
and improved risk prediction after adjustment for conventional risk markers, including C-reactive protein and N-terminal 
 pro-B-type natriuretic peptide. Importantly, changes in high-sensitive troponin T during 3-month follow-up provided inferior 
prognostic information than that of elevated baseline levels. Thus, measurements of high-sensitive troponin T levels might be 
useful in risk stratification of elderly patients with HF. From a clinical point of view, the prognostic value of baseline levels 
seems to be more important than that of changes during follow-up.
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Supplemental Tables 
Supplemental Table 1. Baseline differences between total CORONA population and hs-
cTnT sub-study. 
 
Variable 
CORONA 
Total study 
(n=5011) 
CORONA 
Hs-cTnT sub-study 
(n=1245) 
 
P-value  
Age, years 72.7 (7.1) 71.8 (6.9) <0.001 
Female sex 1180 (23.5) 284 (22.8) 0.583 
Smoking 528 (10.5) 175 (12.1) 0.262 
NYHA Class   0.002 
II 1857 (37.1) 400 (32.1)  
III 3081 (61.5) 830 (66.7)  
IV 73 (1.5) 15 (1.2)  
Ejection Fraction (%) 31 (6) 32 (7) <0.001 
BMI (kg/m2) 27.2 (4.5) 27.3 (4.5) 0.631 
SBP (mmHg) 129 (16.0) 129 (16.0) 0.705 
DBP (mmHg) 76 (8.9) 77 (8.8) 0.015 
Heart rate (beats/min) 72 (11) 71 (11) 0.002 
    
Medical history    
Myocardial infarction 3006 (60.0) 780 (62.7) <0.001 
History of angina pectoris 3570 (71.2) 910 (73.1) <0.001 
Other atherosclerotic disease 1032 (20.6) 243 (19.5) <0.001 
PCI / CABG 1229 (24.5) 262 (21.0) <0.001 
Hypertension 3175 (63.4) 868 (69.7) <0.001 
Diabetes mellitus 1477 (29.5) 325 (26.1) 0.019 
Stroke 624 (12.5) 145 (11.6) 0.438 
Claudication 637 (12.7) 128 (10.3) 0.019 
COPD 109 (2.2) 24 (1.9) 0.588 
    
Laboratory measures    
Total Cholesterol (mmol/L) 5.17 (1.08) 5.22 (1.09) 0.196 
LDL (mmol/L) 3.55 (0.94) 3.64 (0.97) 0.005 
HDL (mmol/L) 1.23 (0.35) 1.23 (0.35) 0.782 
Triglycerides (mmol/L) 2.00 (1.28) 2.00 (1.34) 0.513 
Apo B/Apo A-1 value 0.87 (0.25) 0.88 (0.25) 0.084 
eGFR (mL/min/1.73m2) 57 (14) 58 (14) 0.239 
NT-proBNP (pmol/L) 173 (73-368) 156 (61-339) 0.023 
hs-CRP (mg/L) 3.50 (1.60-7.45) 3.55 (1.60-7.57) 0.482 
    
Medications    
Diuretics (loop / thiazide)   0.006 
     None 677 (13.5) 161 (12.9)  
     One 3977 (79.4) 951 (76.4)  
     Both 357 (7.1) 133 (10.7)  
Aldosterone antagonist 1906 (38.0) 454 (36.5) 0.306 
ACE-inhibitor 3981 (79.4) 1001 (80.4) 0.453 
Angiotensin II receptor blocker 637 (12.7) 128 (10.3) 0.019 
Beta blocker 3722 (74.3) 962 (77.3) 0.029 
Digitalis glycoside 1618 (32.3) 349 (28.0) 0.004 
	
Demographic, clinical and biochemical baseline characteristics stratified in the total 
CORONA study population vs. the current study population with available measurements of 
hs-cTnT levels. Hs-CRP and NT-proBNP levels are displayed as median value (25th-75th 
percentiles). Other variables are shown as numbers (percentage of total) or as mean (standard 
deviation) where appropriate. NYHA, New York Heart Association; BMI, body mass index; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; PCI, percutaneous coronary 
intervention; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary 
disease; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ApoB, apolipoprotein 
B; ApoA-1, apolipoprotein A-1; eGFR, estimated glomerular filtration rate; Hs-CRP, High-
sensitivity C-reactive protein; NT-proBNP, amino-terminal pro-brain natriuretic peptide; 
ACE, angiotensin converting enzyme.  
 
Supplemental Table 2. Multivariable analyses – effects of hs-cTnT quartiles on 
outcomes. 
	
hs-cTnT, quartiles (ng/L) n Events HR (95% CI) P-value Wald 
Primary endpoint 1026 272  
 2. quartile (6.60-13.86)  1.82 (1.12-2.95) 0.015 5.86 
 3. quartile (13.88-25.64)  2.49 (1.54-4.02) <0.001 13.8 
 4. quartile (25.65-390.9)  3.24 (1.96-5.38) <0.001 20.8 
    
All-cause mortality 1026 281  
 2. quartile  1.74 (1.07-2.81) 0.024 5.06 
 3. quartile  2.24 (1.39-3.62) 0.001 11.0 
 4. quartile  2.76 (1.67-4.56) <0.001 15.8 
    
CV mortality 1026 227  
 2. quartile  1.79 (1.04-3.09) 0.035 4.44 
 3. quartile  2.23 (1.30-3.83) 0.004 8.50 
 4. quartile  2.94 (1.68-5.15) <0.001 14.1 
    
CV mortality or hospitalization from WHF  
  1026 367  
 2. quartile  1.06 (0.73-1.53) 0.772 0.08 
 3. quartile  1.19 (0.82-1.73) 0.359 0.84 
  4. quartile     1.80 (1.22-2.66) 0.003 8.71 
	
The table shows quartiles of hs-cTnT levels as predictors of outcome. All Hazard Ratios (HR) 
are given as HR (95% confidence interval), with corresponding (P-value). The multivariable 
regression model includes the following risk factors: left ventricular ejection fraction, NYHA 
class, age, body mass index, diabetes, sex, intermittent claudication, heart rate and 
ApoB/ApoA-1-ratio, NT-proBNP, hs-CRP and estimated glomerular filtration rate.  
	
Supplemental Table 3. Comparisons of hs-cTnT vs. hs-CRP and NT-proBNP as 
predictors of outcome.  
  hs-cTnT hs-CRP NT-proBNP 
Primary endpoint  
 C-statistic 0.682 0.655 0.689 
 P-value NA 0.024 0.602 
   
All-cause mortality  
 C-statistic 0.697 0.682 0.712 
 P-value NA 0.194 0.213 
   
CV mortality  
 C-statistic 0.699 0.681 0.721 
 P-value NA 0.147 0.135 
   
CV mortality and hospitalization from WHF 
 C-statistic 0.682 0.673 0.708 
  P-value NA 0.300 0.019 
 
The table shows C-statistics with corresponding P-values for differences between hs-cTnT, 
hs-CRP and NT-proBNP, respectively, in prediction of outcome. The multivariable regression 
model includes the following risk factors: left ventricular ejection fraction, NYHA class, age, 
body mass index, diabetes, sex, intermittent claudication, heart rate and ApoB/ApoA-1-ratio 
and estimated glomerular filtration rate. 	
